These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38235127)

  • 1. Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America.
    Martinez-Murillo PA; Huttner A; Lemeille S; Medaglini D; Ottenhoff THM; Harandi AM; Didierlaurent AM; Siegrist CA
    Front Immunol; 2023; 14():1279003. PubMed ID: 38235127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.
    Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC
    Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
    Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG;
    Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
    Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
    Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
    Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
    Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.
    Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK;
    J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
    Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK
    Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.
    Huttner A; Combescure C; Grillet S; Haks MC; Quinten E; Modoux C; Agnandji ST; Brosnahan J; Dayer JA; Harandi AM; Kaiser L; Medaglini D; Monath T; ; Roux-Lombard P; Kremsner PG; Ottenhoff TH; Siegrist CA
    Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
    Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
    PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
    ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
    CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
    Boum Y; Juan-Giner A; Hitchings M; Soumah A; Strecker T; Sadjo M; Cuthbertson H; Hayes P; Tchaton M; Jemmy JP; Clarck C; King D; Faga EM; Becker S; Halis B; Gunnstein N; Carroll M; Røttingen JA; Kondé MK; Doumbia M; Henao-Restrepo AM; Kieny MP; Cisse M; Draguez B; Grais RF
    Vaccine; 2020 Jun; 38(31):4877-4884. PubMed ID: 32499066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
    Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
    Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Simon JK; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BG; Welebob C; Hanson ME; Grais RF
    Vaccine; 2022 Nov; 40(46):6599-6606. PubMed ID: 36208978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.
    Antonello J; Grant-Klein RJ; Nichols R; Kennedy SB; Dubey S; Simon JK
    Vaccine; 2020 Jun; 38(31):4885-4891. PubMed ID: 32499064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.